Nulibry (fosdenopterin)

Nulibry (fosdenopterin) is covered only to reduce mortality in FDA‑approved molybdenum cofactor deficiency (MoCD) Type A and is excluded for other MoCD types/diagnoses or if there is no confirmed MOCS1 mutation or the disease is judged too advanced to benefit. Coverage requires genetic confirmation of a MOCS1 mutation, clinical documentation that the patient is likely to derive benefit, prescribing by or consultation with a pediatrician/geneticist/MoCD specialist, adherence to specified age/weight‑based IV dosing/titration, documented safety monitoring, and approvals are granted for 12 months.

"Reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A (FDA‑approved indication)."

Sign up to see full coverage criteria, indications, and limitations.